Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Last Updated: August 13, 2022

Investigational Drug Information for GLPG1690


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for GLPG1690?

GLPG1690 is an investigational drug.

There have been 9 clinical trials for GLPG1690. The most recent clinical trial was a Phase 2 trial, which was initiated on November 5th 2018.

The most common disease conditions in clinical trials are Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, and Fibrosis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].

There are five US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for GLPG1690
TitleSponsorPhase
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic SclerosisGalapagos NVPhase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic SclerosisGalapagos NVPhase 2
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CareGalapagos NVPhase 3

See all GLPG1690 clinical trials

Clinical Trial Summary for GLPG1690

Top disease conditions for GLPG1690
Top clinical trial sponsors for GLPG1690

See all GLPG1690 clinical trials

US Patents for GLPG1690

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GLPG1690 See Plans and Pricing Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) See Plans and Pricing
GLPG1690 See Plans and Pricing Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) See Plans and Pricing
GLPG1690 See Plans and Pricing Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Galapagos NV (Mechelen, BE) See Plans and Pricing
GLPG1690 See Plans and Pricing Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (Mechelen, BE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GLPG1690

Drugname Country Document Number Estimated Expiration Related US Patent
GLPG1690 Argentina AR095280 2033-03-14 See Plans and Pricing
GLPG1690 Australia AU2014231009 2033-03-14 See Plans and Pricing
GLPG1690 Australia AU2017286828 2033-03-14 See Plans and Pricing
GLPG1690 Australia AU2019204539 2033-03-14 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.